Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

GD2-CAR-expressing autologous T-lymphocytes

Genetically modified, autologous T-lymphocytes transduced with a retroviral vector encoding a 14g2a.zeta chimeric antigen receptor (CAR) directed against the disialoganglioside GD2, with potential immunomodulating and antineoplastic activities. Upon intravenous administration, the activated T-lymphocytes target the GD2 antigen on tumor cells and selectively kill those cells. The tumor-associated antigen GD2 is overexpressed on the surface of almost all tumors of neuroectodermal origin.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	tvs-CTL vaccine

GD2-CAR-expressing autologous T-lymphocytes

Search NCI's Drug Dictionary